Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arcus Biosciences Inc (RCUS)
NYSE:RCUS
Holding RCUS?
Track your performance easily
RCUS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.95 - $20.60
Previous Close$16.9
Volume507.21K
Average Volume (3M)653.61K
Market Cap
$1.55B
Enterprise Value$576.12M
Total Cash (Recent Filing)$969.00M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Nov 05, 2024EPS Estimate
-$1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.10
Shares Outstanding91,427,505
10 Day Avg. Volume472,871
30 Day Avg. Volume653,609
Standard Deviation0.23
R-Squared0.04
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.43
Price to Sales (P/S)6.64
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.33
Enterprise Value/Gross Profit4.92
Enterprise Value/Ebitda-2.44
Forecast
1Y Price Target
$33.67Price Target Upside101.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Arcus Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial PresentationThe company plans to present data from the wholly-owned casdatifan 100 mg expansion cohort of the Ph 1/1b ARC-20 trial in clear cell renal cell carcinoma at a medical conference.
Investor InterestInvestor interest in the company has been steadily picking up, with most investors focused on the ARC-20 dose expansion read-out with casdatifan, which is expected to be positive.
Stock Price TargetThere is considerable upside for the stock and the price target has been increased from $35 to $46 on the basis of revised product forecasts.
Bears Say
Clinical SetbacksTIGIT’s repeated setbacks with Roche’s recent failure dampening any momentum Arcus had post-ASCO.
Market SentimentInvestors still largely skeptical on the name, with little near-term improvement in sentiment.
Pipeline ConcernsConcerns over Arcus’ late-stage pipeline are likely to persist.
---
Ownership Overview
40.81% Insiders
16.94% Mutual Funds
31.31% Other Institutional Investors
10.94% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RCUS FAQ
What was Arcus Biosciences Inc’s price range in the past 12 months?
Arcus Biosciences Inc lowest stock price was $12.95 and its highest was $20.60 in the past 12 months.
What is Arcus Biosciences Inc’s market cap?
Currently, no data Available
When is Arcus Biosciences Inc’s upcoming earnings report date?
Arcus Biosciences Inc’s upcoming earnings report date is Nov 05, 2024 which is in 48 days.
How were Arcus Biosciences Inc’s earnings last quarter?
Arcus Biosciences Inc released its earnings results on Aug 08, 2024. The company reported -$1.02 earnings per share for the quarter, beating the consensus estimate of -$1.115 by $0.095.
Is Arcus Biosciences Inc overvalued?
According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued.
Does Arcus Biosciences Inc pay dividends?
Arcus Biosciences Inc does not currently pay dividends.
What is Arcus Biosciences Inc’s EPS estimate?
Arcus Biosciences Inc’s EPS estimate is -$1.
How many shares outstanding does Arcus Biosciences Inc have?
Arcus Biosciences Inc has 91,427,505 shares outstanding.
What happened to Arcus Biosciences Inc’s price movement after its last earnings report?
Arcus Biosciences Inc reported an EPS of -$1.02 in its last earnings report, beating expectations of -$1.115. Following the earnings report the stock price went up 14.025%.
Which hedge fund is a major shareholder of Arcus Biosciences Inc?
Among the largest hedge funds holding Arcus Biosciences Inc’s share is Woodline Partners LP. It holds Arcus Biosciences Inc’s shares valued at 65M.
---
Arcus Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.67 (101.26% Upside)
$33.67 (101.26% Upside)
Blogger Sentiment
Bullish
RCUS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-17.84%
12-Months-Change
Fundamentals
Return on Equity
-41.47%
Trailing 12-Months
Asset Growth
-2.79%
Trailing 12-Months
Company Description
Arcus Biosciences Inc
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
---
RCUS Company Deck
---
RCUS Earnings Call
Q2 2024
0:00 / 0:00
---
RCUS Stock 12 Month Forecast
Average Price Target
$33.67
▲(101.26% Upside)
Technical Analysis
Best Analysts Covering RCUS
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+5.97%
assigned a buy rating 2 days ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +5.97% per trade.
---